Company Description
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.
It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
The company markets its products through a single direct sales force, principally in the United States.
TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Country | United States |
IPO Date | Nov 8, 2019 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 227 |
CEO | Antony Koblish |
Contact Details
Address: 1 Great Valley Parkway Malvern, Pennsylvania United States | |
Website | https://www.telabio.com |
Stock Details
Ticker Symbol | TELA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001561921 |
CUSIP Number | 872381108 |
ISIN Number | US8723811084 |
Employer ID | 45-5320061 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Antony Koblish | Co-founder, President, Chief Executive Officer & Director |
Paul Talmo | Chief Technology Officer |
Roberto E. Cuca J.D. | Chief Financial Officer & Chief Operating Officer |
D. Taylor Ocasio | General Counsel & Corporate Secretary |
Gregory A. Firestone | Chief Commercial Officer |
Jennifer Lou Armstrong | Senior Vice President of Human Resources |
Louisa Smith | Investor Relations Contact Officer |
Megan Smeykal | Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer |
Michael Leonard | Senior Vice President of Technical Operations |
Peter C. Murphy | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SCHEDULE 13G | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 08, 2024 | 10-Q | Quarterly Report |
Nov 07, 2024 | 8-K | Current Report |
Oct 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Oct 28, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 25, 2024 | SC 13D/A | [Amend] Filing |
Oct 24, 2024 | 4 | Filing |
Oct 24, 2024 | 4 | Filing |
Oct 24, 2024 | 4 | Filing |